Results 81 to 90 of about 28,560,894 (288)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus

Терапевтический архив, 2014
AIM. To study the secretion of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 2 (GLP-2) in response to a carbohydrate load in people with risk factors for type 2 diabetes mellitus (DM2) in ...
E A Shestakova, A V Il'in, M V Shestakova, I I Dedov   +3 more
doaj  

Disordered pancreatic and gastrointestinal hormone responses to nutrient stimulation in Zambian children with severe acute malnutrition

Experimental Physiology
Nutrient sensing enables the body to detect and respond to nutrient availability through hormonal regulation. In this study, we examined nutrient‐stimulated hormonal responses in children with severe acute malnutrition (SAM) compared with hospitalized ...
Ellen Besa, Ruth Phiri, Andreck Tembo, Gwen Nayame, Amon Ngongola, Jens Rehfeld, Bolette Hartmann, Gary Frost, Douglas C. Heimburger, Paul Kelly   +9 more
doaj   +1 more source

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot

Biomedicines
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero, David Rodríguez de Vera Gómez, Pablo Rodríguez de Vera Gómez, Luis María Gordillo Fernández   +3 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Gastrointestinal motor function and glycaemic control in diabetes. [PDF]

, 2010
This thesis focuses on the role of gastric emptying and gastrointestinal hormones in the regulation of glycaemia and appetite in health and patients with type 2 diabetes.
Ma, Jing
core  

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Trials
Background The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor analogues or ...
Ebaa Al-Ozairi, Kavita Narula, Alexander D. Miras, Etab Taghadom, Abeer El Samad, Jumana Al Kandari, Anas Alyosef, Anant Mashankar, Werd Al-Najim, Carel W. le Roux   +9 more
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov

, 2023
Nasser M Alorfi, Fahad S Alshehri Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaCorrespondence: Nasser M Alorfi, Pharmacology and Toxicology Department, Faculty of Pharmacy, Umm Al-Qura ...
Alorfi NM, Alshehri FS
core  

Gastrointestinal signals regulating appetite in humans [PDF]

, 2005
Obesity and its associated complications are a significant health problem in industrialized countries. This fact has generated great interest in the role of the gut in the regulation of food intake in the past three decades.
Oesch, Sibylle
core   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source